source
- GSK drops chronic cough drug camlipixant after mixed Phase 3 resultsGSK announced it will stop investing in camlipixant for refractory chronic cough after the drug failed to meet key endpoints in a late-stage trial. The company had run two Phase 3 studies, CALM-1…
- San Diego biotech BlossomHill files for IPO to fund EGFR lung-cancer drug programBlossomHill Therapeutics, a San Diego oncology biotech focused on small‑molecule drugs, has filed an S‑1 registration statement to become a public company. The company, founded in February 2024 by…